Category Archives: Cell Medicine

Contact Information

Available for logged-in reporters only

Newswise The governing board of the California Institute for Regenerative Medicine (CIRM) has awarded two University of California, San Diego researchers almost $3 million in combined funding to pursue new technologies intended to accelerate advances moving stem cell therapies out of the lab and into the clinic.

The funding was part of almost $30 million in new Tools and Technologies awards announced at CIRMs monthly meeting in San Francisco.

Sometimes even the most promising therapy can be derailed by a tiny problem, said Jonathan Thomas, JD, PhD, chair of the CIRM Board. These awards are designed to help find ways to overcome those problems, to bridge the gaps in our knowledge and ensure that the best research is able to keep progressing and move out of the lab and into clinical trials in patients.

Shaochen Chen, PhD, professor in the Department of Nanoengineering in the Jacobs School of Engineering and a member of the Institute of Engineering in Medicine at UC San Diego, received a $1.3 million in CIRM funding for development of 3D bioprinting techniques using human embryonic stem cell-derived heart muscle cells to create new cardiac tissue.

Millions of Americans suffer from cardiovascular disease, specifically congestive heart failure in which a heart valve ceases to work properly. Current treatment often calls for a valve transplant, but donor availability does not meet need.

Chen and colleagues are exploring the possibility of engineering healthy cardiac tissues bioprinted from heart muscle cells, called cardiomyocytes, created from human embryonic stem cells. These tissues could then be implanted in a damaged heart, restoring function.

Shyni Varghese, PhD, associate professor in the Department of Bioengineering at the Jacobs School of Engineering and director of the Bio-Inspired Materials and Stem Cell Engineering Laboratory, received a $1.4 CIRM grant to improve in vivo function of transplanted stem cells.

Vargheses lab focuses upon the complex interactions of cells with their surrounding microenvironment, and how the conditions necessary to promote normal, healthy survival and growth occur.

Read this article:
Two UC San Diego Scientists Receive Stem Cell Technology Grants

By Sheryl Ubelacker, The Canadian Press

TORONTO - Gordie Howe's son says the hockey legend's stroke symptoms have improved since his treatment with stem cells at a Mexican clinic in early December and he wants him to repeat the procedure.

But regenerative medicine experts say there's no scientific evidence such therapies work, and in some cases they can be seriously harmful or even deadly.

The 86-year-old Howe suffered two disabling strokes late last year. In December, the family took him to a Tijuana clinic where he received stem cell injections as part of a clinical trial being run under a licensing agreement with Stemedica Cell Technologies of San Diego, Calif.

The experimental treatment involved injecting neural stem cells into Howe's spinal canal, along with intravenous infusions of mesenchymal stem cells, which are found in bone marrow, fat and umbilical cord blood.

Marty Howe said his father can walk again, his speech is improving and he is regaining some of the weight he lost following the strokes.

"After his stem cell treatment, the doctor told us it was kind of an awakening of the body, and it was all that," he told The Canadian Press while in Calgary for a hockey promotion event Tuesday. "They call it the miracle of stem cells and it was nothing less than a miracle."

However, experts in the field question whether stem cells are responsible for Howe's improvement and caution that most so-called stem cell therapies have not gone through rigorous scientific trials, nor have they been approved as treatments by Health Canada or the U.S. Food and Drug Administration.

Mick Bhatia, director of McMaster University's Stem Cell and Cancer Research Institute, said there are many unknowns in Howe's case, such as how many stem cells were administered, were tests done to see whether they migrated to the targeted area of the body, and did they take up residence where they might have some effect or simply disappear?

"Is this a transient effect, or is it really a perceived or somewhat of a placebo effect and is there something really happening? Scientifically and biologically that is important," Bhatia said Wednesday from Hamilton.

Visit link:
Howe's stem cell treatment raises concerns

Boston, MA (PRWEB) January 29, 2015

Dr. James Sherley, Director of the new biotech start-up Asymmetrex, LLC (formerly known as The Adult Stem Cell Technology Center, LLC) is looking forward to four upcoming opportunities in 2015 to continue to impress both academic and industry audiences with his companys very frank take on what is needed to accelerate progress in stem cell medicine.

Asymmetrex has set the focus for its efforts on adult stem cells that are found in the organs and tissues of children and adults. Unlike human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs), adult stem cells are free of induced mutations, are not tumor-forming, and have the essential ability to continuously regenerate mature human tissue cells like those in children and adults. To date, hESCs and iPSCs have only been able to regenerate immature cells, and even those not continuously.

Previously, the two main challenges hindering wider use of adult stem cells for drug development and medical therapies have been difficulty producing them and difficulty counting them. Asymmetrex has reported, and in many cases secured patents for, new technologies that reduce or eliminate both of these challenges. At the coming conferences, Dr. Sherley will describe the companys most recent technological advances in this regard and discuss the science that led to them.

In particular, he will highlight the companys newest technology developed with partner AlphaSTAR Corporation for estimating adult stem cell number in any human tissue. The two companies are developing the new technology as an assay to detect drug candidates that will fail in expensive pre-clinical animal studies and clinical trials because of intolerable toxicity against tissue stem cells. By screening-out such drugs earlier in the drug development process, Asymmetrex and AlphaSTAR estimate that together they could save the U.S. pharmaceutical industry $4-5 billion each year.

The four scheduled conferences include the 7th Annual Predictive Toxicology Summit, February 16-18, in London; the 5th World Congress on Cell and Stem Cell Research, March 23-25, in Chicago; the 2015 Annual Meeting at Experimental Biology, March 28-April 1, in Boston; and the Inaugural 3D Cellular Models Conference, June 11-12, also in Boston.

The breadth of conference topics reflects the many important roles that adult tissue stem cells play in human biology and cellular medicine. Dr. Sherley offers that, Because of the importance of adult stem cells in normal body function, it is not surprising that Asymmetrexs technologies impact so many different facets of stem cell biology, regenerative medicine, and drug development.

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrexs founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The companys patent portfolio contains biotechnologies that solve the two main technical problems production and quantification that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Currently, Asymmetrexs focus is employing its technological advantages to develop facile methods for monitoring adult stem cell number and function in clinically important human tissues.

See the original post here:
Asymmetrex Scheduled to Present Unique Perspectives in Stem Cell Biology and Recent Advances in Technologies for Adult ...

MIAMI (PRWEB) January 29, 2015

Regenestem Network, the worlds largest membership network of regenerative medicine practitioners, has announced the launch of a new stem cell clinic in Oaxaca, Mexico. The new facility, offering the most advanced cellular medicine protocols and techniques available is in partnership with Ulises Cervera, M.D. a neurologist coming from the Children's Hospital of Morelia, Mexico.

The new Oaxaca facility will offer the most advanced protocols and techniques available in stem cell medicine to patients from across Mexico and around the world.

Global Stem Cells Group and Regenestem Network are expanding the companys clinical presence worldwide by partnering with experienced and qualified regenerative medicine physicians to open new clinics licensed and developed under the Regenestem banner.

In 2014, Global Stem Cells Group expanded the Regenestem Networks global presence to 20 countries.

Regenestem offers stem cell treatments to help treat a variety of diseases and conditions including arthritis, autism, chronic obstructive pulmonary disease (COPD), diabetes, and pain due to injuries at various facilities worldwide. Regenestem Oaxaca will have an international staff experienced in administering the latest in cellular therapies.

Regenestem is certified for the medical tourism market, and staff physicians are board-certified or board-eligible. Regenestem clinics provide services in more than 10 specialties, attracting patients from the United States and around the world.

The Global Stem Cells Group and Regenestem are committed to the highest of standards in service and technology, expert and compassionate care, and a philosophy of exceeding the expectations of their international patients.

For more information, visit the Regenestem Network website, email info(at)regenstem(dot)com, or call 305-224-1858.

About Regenestem: Regenestem Network, a division of the Global Stem Cells Group, Inc., is an international medical practice association committed to researching and producing comprehensive stem cell treatments for patients worldwide. Having assembled a highly qualified staff of medical specialistsprofessionals trained in the latest cutting-edge techniques in cellular medicineRegenestem continues to be a leader in delivering the latest protocols in the adult stem cell arena.

More:
Global Stem Cells Group and Regenestem Network Announce Launch of New Stem Cell and Regenerative Medicine Clinic in ...

Pluripotent stem cells are cells capable of indefinite expansion and then differentiation into any and all of the cell types of the human body. Examples of pluripotent stem cells are human embryonic stem cells (hES) and induced pluripotent stem (iPS) cells. These stem cells potentially offer a new technology platform for the manufacture of a wide array of cell types designed to be transplanted into the body to restore healthy tissue function.

BioTime and its subsidiaries are focused on developing and commercializing a broad portfolio of innovative cellular therapeutics and diagnostic products, while also continuing to build value in other ways, such as through the addition of new patents to our industry-leading intellectual property estate, said Dr. Michael D. West, Ph.D., BioTimes Chief Executive Officer. We are making significant strides in patenting our core platform of pluripotent stem cell technology and strengthening our competitive position in regenerative medicine. For the first time in history, pluripotent stem cells offer a means of manufacturing previously rare and valuable human cell types in a cost-effective manner and on an industrial scale. We plan to utilize our strengthened patent position to drive value for our shareholders as the field of regenerative medicine begins to address the large and growing markets associated with chronic and age-related degenerative disease.

New Patents Owned by BioTime or one of its subsidiaries:

European patent 1809739 This issued patent claims cell culture media for the proliferation and scale-up of hES cells. The patent issuing in Austria, France, Germany, Ireland, Switzerland and Sweden provides a propagation medium for culturing hES cells in the laboratory such that the cells proliferate without differentiating as defined in the claims. The technology allows the user to rapidly produce high-quality embryonic stem cells for use in therapy and drug discovery, in a cost-effective and controlled manner, from defined or commercially available reagents. The patent is therefore useful for manufacturing products from hES cells. Patents in the same family have previously issued in the United States, Australia, UK, Israel, Singapore and Hong Kong, with additional applications pending.

Canada patent 2559854 and China patent ZL200580008779.0 These patents claim a differentiation method for making high purity heart muscle preparations from pluripotent stem cells such as hES cells suitable for use in regenerative medicine. The issued claims cover methods wherein the pluripotent stem cells are treated with specific growth factors and differentiation conditions to manufacture beating heart muscle cells. The patents are therefore useful in the manufacture and commercialization of heart muscle cells for research, for the testing of drugs on the heart, and potentially for regenerating heart muscle following a heart attack or heart failure. Patents in the same family have previously issued in the United States, Australia, UK, Israel, Japan and Singapore, with additional applications pending.

South Korea patent1543500B The patent titled, Hematopoietic Cells from Human Embryonic Stem Cells, claims methods for using pluripotent stem cell technology for inducing immune tolerance of cells transplanted into a patient (that is, in helping to prevent the rejection of transplanted cells). As such, the patent claims may be useful in commercializing diverse types of transplantable cells. Patents in the same family have previously issued in Australia, UK, Israel, Japan and Singapore, with additional applications pending.

Canada patent 2468335 The patent describes cartilage-forming cells derived from human pluripotent stem cells such as hES cells. The claims in the patent relate to a system of making the cartilage-forming cells using factors of the transforming growth factor beta (TGF-beta) family, of immortalizing the cells with the human telomerase gene, pharmaceutical formulations of the cells for therapeutic use in arthritis, as well as other claims. The patent is therefore useful for the manufacture of such cells for use in research and potentially in therapy for a number of applications in orthopedic medicine. Patents in the same family have previously issued in the United States, Australia, Singapore, Israel and South Korea, with additional applications pending.

Israel patent208116 The patent titled, Differentiation of Primate Pluripotent Stem Cells to Hematopoietic Lineage Cells, claims methods for the manufacture of dendritic cells from primate pluripotent stem cells. Dendritic cells are cells that trigger an immune response to a particular molecule. Often their role is to stimulate the immune system to attack microorganisms such as bacteria. BioTimes subsidiary Asterias Biotherapeutics is developing hES cell-derived dendritic cells modified to trigger an immune response to specific antigens related to cancer. A patent in the same family has previously issued in the United States, with additional applications pending.

Singapore patent 188098 The patent titled, Synthetic Surfaces for Culturing Stem Cell Derived Cardiomyocytes, claims certain polymers upon which heart muscle cells derived from pluripotent stem cells may be cultured. The patent is potentially useful for the manufacture of human heart muscle cells for drug screening and toxicity testing and for use in the manufacture of such cells for transplantation into human subjects for the treatment of heart disease. A patent in the same family has previously issued in the United States, with additional applications pending.

Singapore patent 176957 The patent titled, Differentiated Pluripotent Stem Cell Progeny Depleted of Extraneous Phenotypes, claims methods for the purification of pluripotent stem cell-derived oligodendrocytes by the removal of contaminating cells that display an antigen called epithelial cell adhesion molecule (EpCAM). This method is potentially useful in the purification of such oligodendrocytes prior to their use in research or human therapy. Patents in the same family have previously issued in the United States and China, with additional applications pending.

Read more from the original source:
BioTime Announces Issuance of 14 New Patents in the Fields of Regenerative Medicine, Stem Cell Technology, and Cancer ...

Naples, Florida (PRWEB) January 23, 2015

The Miami Stem Cell Treatment Center announces a series of free public seminars on the use of adult stem cells for various degenerative and inflammatory conditions. They will be provided by Dr. Thomas A. Gionis, Surgeon-in-Chief and Dr. Nia Smyrniotis, Medical Director and Surgeon.

The first seminar will be held on Sunday, January 25, 2015, at 11:00am, 1:00pm and 3:00pm at the Hilton Naples, 5111 Tamiami Trail North, Naples, FL 34103. Please RSVP at (561) 331-2999.

The Miami Stem Cell Treatment Center (Miami; Boca Raton; Orlando), along with sister affiliates, the Irvine Stem Cell Treatment Center (Irvine; Westlake Villages, Ca.) and the Manhattan Regenerative Medicine Medical Group (Manhattan, New York), abide by approved investigational protocols using adult adipose derived stem cells (ADSCs) which can be deployed to improve patients quality of life for a number of chronic, degenerative and inflammatory conditions and diseases. ADSCs are taken from the patients own adipose (fat) tissue (found within a cellular mixture called stromal vascular fraction (SVF)). ADSCs are exceptionally abundant in adipose tissue. The adipose tissue is obtained from the patient during a 15 minute mini-liposuction performed under local anesthesia in the doctors office. SVF is a protein-rich solution containing mononuclear cell lines (predominantly adult autologous mesenchymal stem cells), macrophage cells, endothelial cells, red blood cells, and important Growth Factors that facilitate the stem cell process and promote their activity.

ADSCs are the bodys natural healing cells - they are recruited by chemical signals emitted by damaged tissues to repair and regenerate the bodys injured cells. The Miami Stem Cell Treatment Center only uses Adult Autologous Stem Cells from a persons own fat No embryonic stem cells are used; and No bone marrow stem cells are used. Current areas of study include: Emphysema, COPD, Asthma, Heart Failure, Heart Attack, Parkinsons Disease, Stroke, Traumatic Brain Injury, Lou Gehrigs Disease, Multiple Sclerosis, Lupus, Rheumatoid Arthritis, Crohns Disease, Muscular Dystrophy, Inflammatory Myopathies, and degenerative orthopedic joint conditions (Knee, Shoulder, Hip, Spine).

For more information, or if someone thinks they may be a candidate for one of the adult stem cell protocols offered by the Miami Stem Cell Treatment Center, they may contact Dr. Gionis or Dr. Smyrniotis directly at (561) 331-2999, or see a complete list of the Centers study areas at: http://www.MiamiStemCellsUSA.com.

About the Miami Stem Cell Treatment Center: The Miami Stem Cell Treatment Center, along with sister affiliates, the Irvine Stem Cell Treatment Center and the Manhattan Regenerative Medicine Medical Group, is an affiliate of the California Stem Cell Treatment Center / Cell Surgical Network (CSN); we are located in Boca Raton, Orlando, Miami and The Villages (opening soon), Florida. We provide care for people suffering from diseases that may be alleviated by access to adult stem cell based regenerative treatment. We utilize a fat transfer surgical technology to isolate and implant the patients own stem cells from a small quantity of fat harvested by a mini-liposuction on the same day. The investigational protocols utilized by the Miami Stem Cell Treatment Center have been reviewed and approved by an IRB (Institutional Review Board) which is registered with the U.S. Department of Health, Office of Human Research Protection (OHRP); and our studies are registered with Clinicaltrials.gov, a service of the U.S. National Institutes of Health (NIH).

For more information, visit our websites: http://www.MiamiStemCellsUSA.com, http://www.IrvineStemCellsUSA.com , or http://www.NYStemCellsUSA.com.

Link:
The Miami Stem Cell Treatment Center Announces Adult Stem Cell Public Seminars in Naples, Florida

MIAMI (PRWEB) January 22, 2015

Regenestem, a division of the Global Stem Cells Group, Inc., has announced the launch of a new stem cell treatment center in Veracruz, Mexico. The new facility offers the most advanced protocols and techniques in cellular medicine to patients from around the world.

The opening of Regenestem Veracruz is in partnership with Eleuterio Arrieta, M.D., Director of Santa Teresita Hospital in Veracruz. Dr. Arrieta has extensive experience in management of chronic degenerative diseases with autologous stem cell therapies, expertise he will use to deliver cutting edge therapies and follow-up treatment under the Regenestem brand in Veracruz.

Under the direction of Global Stem Cells Group, Regenestem is expanding its clinical presence worldwide by partnering with qualified physicians experienced in stem cell therapies to open new clinics, licensed and developed under the Regenestem banner.

In 2014, Global Stem Cells Group expanded the Regenestem Networks presence to 20 countries, adding new state-of-the-art regenerative medicine facilities to the company's growing global presence.

Regenestem offers stem cell treatments to help with a variety of diseases and conditions including arthritis, autism, chronic obstructive pulmonary disease (COPD), diabetes, and pain due to injuries at various facilities worldwide. Regenestem Veracruz will have an international staff experienced in administering the leading cellular therapies available.

Regenestem is certified for the medical tourism market, and staff physicians are board-certified or board-eligible. Regenestem clinics provide services in more than 10 specialties, attracting patients from the United States and around the world.

The Global Stem Cells Group and Regenestem are committed to the highest of standards in service and technology, expert and compassionate care, and a philosophy of exceeding the expectations of their international patients.

For more information, visit the Regenestem Network website, email info(at)regenstem(dot)com, or call 305-224-1858.

About Regenestem:

Continue reading here:
Regenestem Network, a division of Global Stem Cells Group, Announces Launch of New Stem Cells and Regenerative ...

The International Society for Stem Cell Research's McEwen Award recipient Hans Clevers extends breakthrough work

CHICAGO -- The International Society for Stem Cell Research (ISSCR) has awarded Dr. Hans Clevers, senior author on two important papers published recently in the scientific journal Cell, the society's McEwen Award for Innovation. The papers describe the development of a culturing system for human liver stem cells, as well as stem cells from pancreatic cancer, discoveries with the potential to revolutionize liver transplantation and aid in the fight against pancreatic cancer, respectively.

Clevers is a professor at the Hubrecht Institute and president of the Royal Netherlands Academy of Arts and Sciences. He shares the McEwen Award for Innovation with Dr. Irving Weissman, Stanford School of Medicine, for the identification, prospective purification and characterization of somatic (adult) tissue-associated stem cells and advancement of this research toward clinical applications.

"These new discoveries by Hans Clevers extend the work for which he was awarded the McEwen Award, the ISSCR's most prestigious award," Dr. Rudolf Jaenisch, ISSCR president, said. "The innovative approach Dr. Clevers took in the gut has borne fruit and proven the basis of these significant advances in the liver and pancreas, which hold great promise for the study of and treatments for diseases impacting these organs."

Organoids

Until recently, it appeared impossible to keep healthy or diseased tissue from patients alive under laboratory conditions, let alone multiply it. However, in 2009, the research group headed by Clevers described a revolutionary culturing method that allowed the culturing of mini-guts from single mouse intestine stem cells. These organoids are functional miniature organs that can grow in tissue culture. The same research group now adds a culturing system for liver stem cells and stem cells from pancreatic cancer to their record. In the future, cultured stem cells could conceivably replace donor organs for transplantation. They also offer prospects for personalized medicine, the development of treatments specifically geared to individual patients.

Cultured Liver Stem Cells

The technology described in Cell can be used for the long-term replication in the laboratory of minute amounts of tissue harvested from a healthy or diseased liver. Over a period of four months, the equivalent of a full-grown liver can be cultured from a single liver stem cell. All analyses show that this cultured tissue is genetically the same as healthy liver tissue and is very stable.

The cultured human mini-livers have already been successfully transplanted in mice with liver damage. This is the first step toward using this cultured liver tissue to replace donor livers for transplantation. As such, this technology could solve the worldwide shortage of donor livers. Moreover, this technology offers future potential for personalized medicine. Organoids could, for instance, be grown from the tissue of patients suffering from genetic liver diseases, so that drugs could be tested on this patient material first, before being administered to the patients themselves. Examples of such diseases are alpha-1 antitrypsin deficiency and Alagille Syndrome.

Pancreatic Stem Cells

Read more:
Scientists announce revolutionary culturing technique for liver and pancreas

Researchers at the Stanford University School of Medicine have discovered the stem cell in mice that gives rise to bone, cartilage and a key part of bone marrow called the stroma.

In addition, the researchers have charted the chemical signals that can create skeletal stem cells and steer their development into each of these specific tissues. The discovery sets the stage for a wide range of potential therapies for skeletal disorders such as bone fractures, brittle bones, osteosarcoma or damaged cartilage.

A paper describing the findings will be published Jan. 15 in Cell.

"Millions of times a year, orthopedic surgeons see torn cartilage in a joint and have to take it out because cartilage doesn't heal well, but that lack of cartilage predisposes the patient to arthritis down the road," said Michael Longaker, MD, a professor of plastic and reconstructive surgery at Stanford and a senior author of the paper. "This research raises the possibility that we can create new skeletal stem cells from patients' own tissues and use them to grow new cartilage." Longaker is also co-director of the Stanford Institute for Stem Cell Biology and Regenerative Medicine.

An intensive search

The researchers started by focusing on groups of cells that divide rapidly at the ends of mouse bones, and then showed that these collections of cells could form all parts of bone: the bone itself, cartilage and the stroma -- the spongy tissue at the center of bones that helps hematopoietic stem cells turn into blood and immune cells. Through extensive effort, they then identified a single type of cell that could, by itself, form all these elements of the skeleton.

The scientists then went much further, mapping the developmental tree of skeletal stem cells to track exactly how they changed into intermediate progenitor cells and eventually each type of skeletal tissue.

"Mapping the tree led to an in-depth understanding of all the genetic switches that have to be flipped in order to give rise to more specific progenitors and eventually highly specialized cells," said postdoctoral scholar Charles Chan, PhD, who shares lead authorship of the paper with postdoctoral scholar David Lo, MD, graduate student James Chen and research assistant Elly Eun Young Seo. With that information, the researchers were able to find factors that, when provided in the right amount and at the right time, would steer the development of skeletal stem cells into bone, cartilage or stromal cells.

"If this is translated into humans, we then have a way to isolate skeletal stem cells and rescue cartilage from wear and tear or aging, repair bones that have nonhealing fractures and renew the bone marrow niche in those who have had it damaged in one way or another," said Irving Weissman, MD, professor of pathology and of developmental biology, who directs the Stanford Institute for Stem Cell Biology and Regenerative Medicine. Weissman, the other senior author of the paper, also holds the Virginia and Daniel K. Ludwig Professorship in Clinical Investigation in Cancer Research.

Reprogramming fat cells

Go here to see the original:
Stanford researchers isolate stem cell that gives rise to bones, cartilage in mice

MIAMI (PRWEB) January 14, 2015

Citing fast-paced growth and the need for more space to accommodate its expanding operations, Global Stem Cells Group CEO Benito Novas has announced plans to move the organizations headquarters from Sunrise, Florida to the Miami Lakes Corporate Center. The new location more than doubles the space for the international stem cell and regenerative medicine company's corporate offices.

Since opening in 2012 under the Regenestem brand, Global Stem Cells Group and its six operating companies have grown exponentially, establishing partnerships with stem cell clinics, hospitals, researchers and physicians in the Philippines, South America and Europe.

The new Global Stem Cells Group facility provides state-of-the-art space for our entire team to drive innovation through our research and development initiatives, and support partnering activities with our biotechnology products and education programs, Novas says. We now have the space to continue the fast-paced growth of our companies and advance the development of new stem cell and regenerative medicine technologies that will benefit patients worldwide.

The new corporate headquarters, scheduled to open January 15, 2015, are located in the Miami Lakes Corporate Center, 14750 NW 77th Court, Suite 304 Miami Lakes, FL 33016.

For more information visit the Global Stem Cells website, email bnovas(at)regenestem(dot)com, or call 305-224-1858.

About the Global Stem Cells Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions.

With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Groups corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

Read the original:
Global Stem Cells Group to Move Headquarters to Larger Miami Lakes Office Complex